The inhibition of KDM4C has been shown to suppress GBM cell proliferation and tumorigenesis, prolonging survival in mouse xenograft models [218, 219], suggesting KDM4C inhibition as a potential therapeutic strategy for GBM. This evidence concerns the gene KDM4C and glioblastoma.